Open Market JournalPortfolio
← Journal
MacroCautiousRegime · R3: company-level growth theses remain credible, but weak broad-market and technology momentum, narrow participation, and a 10.10% portfolio drawdown leave the growth trend unconfirmed.

Monday plan: hold the live book while growth leadership seeks confirmation

The portfolio will enter Monday unchanged, with MSFT and NVDA carrying the growth thesis while XLE and XLV offset some of the pressure from weak market participation. Friday's relative performance was encouraging, but the 10.10% drawdown, weak technology momentum, and VIX at 19.45 keep conviction cautious.

Published Oct 26, 2026Open Market Journal3 min readAI-assisted research · methodologyNot investment advice

Resulting portfolio change1 new • 1 exit
  • Opened XLE at 14%
  • Exited META from 14%

Prior plan grade: B+. Holding the book steady worked on Friday: the portfolio gained 0.08% while SPY fell 0.52%, with MSFT and XLE offsetting weakness elsewhere.

Since Last Session

Friday's prior book gained 0.08% versus a 0.52% decline in SPY. MSFT rose 0.66% and XLE gained 2.6%. AMZN fell 0.95%, NVDA declined 0.59%, and XLV lost 1.11%.

Regime Check

Regime: R3. Company-level growth theses remain credible, but the market still lacks a confirmed growth trend.

Supporting: MSFT gained 0.66% on Friday and retains positive 60-day momentum. XLE has positive 20-day and 60-day momentum, while reports of intercepted missiles and drones keep energy supply risk active. XLV also retains positive momentum across both periods. A reported $40 billion SpaceX debt deal for AI chips supports the view that large-scale compute spending remains active.

Contradicting: SPY has negative 20-day and 60-day momentum, while QQQ is weaker across both periods. NVDA and AMZN also have negative momentum over both windows. IWM remains weak, financials fell on Friday, VIX is 19.45, and the portfolio is in drawdown-review at a 10.10% drawdown.

Plan for Monday

No allocation change is being made in this morning report. The portfolio will enter Monday with Friday's symbols and weights intact, and any new decision will remain separate from this publication.

The open needs to show that MSFT can preserve its relative strength and that NVDA and AMZN can stabilize rather than deepen the technology decline. XLE should retain support if regional supply concerns remain active. XLV needs to resume its broader positive trend after Friday's weakness. A weak open led by semiconductors and cloud platforms, without support from broader participation, would argue against increasing growth exposure later in the day.

Positioning

2 of 6 lines changed · weights sum to 100% · published Oct 26, 2026
  1. XLE14%was 0%StrengthenedHold the existing weight.

    XLE gained 2.6% on Friday, retains positive momentum, and regional security risks continue to support the supply-risk thesis.

  2. META0%was 14%Exit 14 pts

    No longer held in this published portfolio.

  3. MSFT29%unchangedStrengthenedHold the existing weight.

    MSFT gained 0.66% on Friday while SPY fell 0.52%, and its 60-day momentum remains positive.

  4. AMZN15%unchangedWeakenedHold without adding.

    AMZN fell 0.95% on Friday and has negative 20-day and 60-day momentum, but the packet contains no company-specific thesis break.

  5. NVDA26%unchangedWeakenedHold without adding.

    NVDA fell 0.59% on Friday and remains weak across both momentum windows, while compute demand and institutional ownership still support the longer-term thesis.

  6. XLV16%unchangedIntactHold the existing weight.

    XLV fell 1.11% on Friday, but its 20-day and 60-day momentum remain positive.

Institutional Signals

The filings remain slow-moving context. Pershing Square reported AMZN at 17.4% and MSFT at 15.3% of its portfolio in its May filing, supporting the durability of the cloud and enterprise software theses. Bridgewater's August filing included NVDA at 3.2%, while Scion's older filing also disclosed NVDA exposure. These positions support long-horizon conviction in the companies, but they don't override current price weakness or justify adding before growth participation improves.

Berkshire's concentration in a small group of durable businesses reinforces the case for keeping the portfolio focused on its strongest theses. It doesn't provide a direct signal on the current XLE or XLV positions.

What Could Break It

The growth thesis would weaken materially if a top-three hyperscaler cuts or defers 2027 capital spending, Azure or AWS growth decelerates while investment rises, or Nvidia reports weaker demand and gross-margin guidance. Persistent weakness across MSFT, NVDA, and AMZN alongside deteriorating market participation would challenge the current concentration.

The XLE thesis would break if Middle East supply tensions ease materially and crude reverses its breakout while energy momentum turns negative. XLV would lose its purpose in the book if health care leadership fades as broad-market participation decisively improves. Any further portfolio loss while the book remains in drawdown-review would require stricter scrutiny of the weakest growth theses before the separate pre-close decision cycle.

Sources and evidence

  1. SpaceX closes $40 billion debt deal for AI chips, Elon Musk says · CNBC
  2. More pain may be coming for the AI trade. Why I’m not giving up on it · CNBC
  3. I paid off $11,000 of credit card debt in 18 months while still traveling, shopping and living my life · CNBC
  4. Volkswagen to build $4bn Audi SUV factory in US despite job cuts at home · The Guardian
  5. Saudi Arabia says it intercepted missiles and drones from Iran-backed Houthis · CNBC
  6. Interest rates unlikely to reach 4.75% by next summer, say City economists · The Guardian
  7. Retail leads the way on paternity leave as government urged to improve offer · The Guardian
  8. What next for France as riots rattle markets? Three questions facing investors ahead of more protests · CNBC
  9. American embassies tighten security as Iran threat warnings intensify ahead of U.S. midterm elections · CNBC
  10. Retail investors are not more sophisticated than 30 years ago, says former hedge fund manager · CNBC
  11. Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer · CNBC
  12. Nvidia's role as AI financier faces first big test as neoclouds take market hit · CNBC